<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029612449197</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029612449197</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antiplatelet Therapy</article-title>
<subtitle>Aspirin Resistance and All That Jazz!</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Divani</surname>
<given-names>Afshin A.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029612449197">1</xref>
<xref ref-type="aff" rid="aff2-1076029612449197">2</xref>
<xref ref-type="corresp" rid="corresp1-1076029612449197"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zantek</surname>
<given-names>Nicole D.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-1076029612449197">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Borhani-Haghighi</surname>
<given-names>Afshin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-1076029612449197">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rao</surname>
<given-names>Gundu H. R.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-1076029612449197">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029612449197"><label>1</label>Department of Neurology, University of Minnesota, Minneapolis, MN, USA</aff>
<aff id="aff2-1076029612449197"><label>2</label>Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA</aff>
<aff id="aff3-1076029612449197"><label>3</label>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA</aff>
<aff id="aff4-1076029612449197"><label>4</label>Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran</aff>
<author-notes>
<corresp id="corresp1-1076029612449197">Afshin A. Divani, Department of Neurology, University of Minnesota, 420 Delaware St S.E., MMC 295, Minneapolis, MN 55455, USA Email: <email>divani@umn.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>18</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Platelets play a crucial role in the pathogenesis of atherosclerosis, thrombosis, and stroke. Aspirin used alone or in combination with other antiplatelet drugs has been shown to offer significant benefit to patients at high risk of vascular events. Resistance to the action of aspirin may decrease this benefit. Aspirin resistance has been defined by clinical and/or laboratory criteria; however, detection by laboratory methods prior to experiencing a clinical event will likely provide the greatest opportunity for intervention. Numerous laboratory methods with different cutoff points have been used to evaluate the resistance. Noncompliance with aspirin treatment has also confounded studies. A single assay is currently insufficient to establish resistance. Combinations of results to confirm compliance and platelet inhibition may identify “at-risk” individuals who truly have aspirin resistance. The most effective strategy for managing patients with aspirin resistance is unknown; however, studies are currently underway to address this issue.</p>
</abstract>
<kwd-group>
<kwd>antiplatelet therapy</kwd>
<kwd>acetylsalicylic acid</kwd>
<kwd> stroke</kwd>
<kwd>thromboxane</kwd>
<kwd>prostacycline</kwd>
<kwd>cyclooxygenase</kwd>
<kwd>arachidonic acid</kwd>
<kwd>vascular disease</kwd>
<kwd>aspirin resistance</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/February 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029612449197">
<title>Introduction</title>
<p>Platelets play a very important role in the pathogenesis of acute vascular events leading to thrombosis of the coronary and cerebral arteries. Blockage of these arteries leading to regional ischemia of heart and brain tissues precipitates heart attack and stroke. In 1897, acetylsalicylic acid (ASA) was commercially produced (and named “aspirin”) by modifying salicylic acid by a German chemist, Felix Hoffman.<sup>
<xref ref-type="bibr" rid="bibr1-1076029612449197">1</xref>
</sup> Since the publication of University of Minnesota-educated Dr Lawrence Craven’s clinical observations,<sup>
<xref ref-type="bibr" rid="bibr1-1076029612449197">1</xref>
</sup> clinical trials have proven aspirin’s role in preventing vascular events. Therefore, aspirin has been the drug of choice for over half a century for the primary and secondary prophylaxis of thrombotic events. Despite extensive use of aspirin as an antiplatelet medication for primary or secondary prevention of vascular thrombosis, there is considerable concern about the degree of protection it offers. In this review, we explain the phenomenon of “aspirin resistance,” discuss the limitations of aspirin therapy, and suggest methods to monitor “at-risk” individuals. Ability to monitor and determine at-risk patients will provide opportunities for the clinicians to customize antiplatelet therapies.</p>
</sec>
<sec id="section2-1076029612449197">
<title>Aspirin Guidelines for Primary and Secondary Prevention of Stroke</title>
<p>Results obtained from the clinical trials have led to the acceptance of aspirin therapy for primary and secondary prevention of vascular events and stroke. Aspirin has been approved by the United States Food and Drug Administration (FDA) as 1 of the 4 antiplatelet therapy agents for noncardioembolic stroke or transit ischemic attack (TIA).<sup>
<xref ref-type="bibr" rid="bibr2-1076029612449197">2</xref>
</sup> While approved in the United States for primary prevention, aspirin is not approved in other countries. For example, aspirin is only licensed for secondary prevention in the United Kingdom.</p>
<p>Published guidelines concerning primary and secondary prevention of stroke have consistently recommended the use of aspirin as the first choice of antiplatelet therapy in an appropriate group of patients. In 2011, the American Heart Association/American Stroke Association (AHA/ASA)<sup>
<xref ref-type="bibr" rid="bibr3-1076029612449197">3</xref>
</sup> recommended the use of aspirin for the primary prevention of cardiovascular events and stroke in persons with a 10-year risk of cardiovascular events of 6% to 10% (Class I; Level of Evidence A), where the benefits outweigh the risks associated with the treatment. However, the use of aspirin is not recommended for the prevention of first stroke in low-risk persons (Class III, Level of Evidence A) nor in persons with diabetes in the absence of other established CVD (Class III; Level of Evidence B). For secondary prevention of stroke in patients with noncardioembolic stroke or TIA,<sup>
<xref ref-type="bibr" rid="bibr2-1076029612449197">2</xref>
</sup> the AHA/ASA recommended aspirin therapy (50-325 mg/d) alone (Class I; Level of Evidence A), the combination of aspirin (25 mg) and extended-release dipyridomale (200 mg) twice daily (Class I; Level of Evidence B), or clopidogrel (75 mg) alone (Class IIa; Level of Evidence B) as viable options for initial therapy. Combined use of aspirin and clopidogrel is not recommended for routine secondary prevention of stroke and TIA (Class III; Level of Evidence A) due to increased risk of hemorrhage. In cardioembolic stroke, the use of aspirin alone is recommended only when a patient is unable to take oral anticoagulants (Class I; Level of Evidence A). The American College of Cardiology Foundation/AHA<sup>
<xref ref-type="bibr" rid="bibr4-1076029612449197">4</xref>
</sup> recommended aspirin (75-325 mg/d) for the prevention of myocardial infarction (MI) in patients with extracranial carotid and/or vertebral arteries disease (Class I, Level of Evidence: A). If the same patient presents with a history of stroke or TIA, the same guidelines recommend the use of aspirin alone (75-325 mg/d), clopidogrel alone (75 mg/d), or the combination of aspirin and extended-release dipyridomale (25 and 200 mg twice daily), respectively (Class I, Level of Evidence: B).</p>
</sec>
<sec id="section3-1076029612449197">
<title>Clinical Trials Using Aspirin as an Antiplatelet</title>
<p>Numerous clinical studies have assessed the safety and efficacy of aspirin use for primary and secondary stroke prevention. Detailed discussion of past and ongoing trails is outside the scope of this review. However, the clinical studies that have used aspirin for stroke prevention are outlined in Table <xref ref-type="table" rid="table1-1076029612449197">1</xref>.</p>
<table-wrap id="table1-1076029612449197" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical Trials for the Use of Aspirin for Stroke Prevention<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-1076029612449197" xlink:href="10.1177_1076029612449197-table1.tif"/>
<graphic alternate-form-of="table1-1076029612449197" xlink:href="10.1177_1076029612449197-table1a.tif"/>
<graphic alternate-form-of="table1-1076029612449197" xlink:href="10.1177_1076029612449197-table1b.tif"/>
<graphic alternate-form-of="table1-1076029612449197" xlink:href="10.1177_1076029612449197-table1c.tif"/>
<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Title</th>
<th>Design</th>
<th>Interventions</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NINDS</td>
<td>Antiplatelet Therapy to Prevent Stroke in African Americans</td>
<td>Phase IV Randomized Double-Blind</td>
<td>Aspirin Ticlopidine</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Aspirin vs Anticoagulants in Symptomatic Intracranial Stenosis (AVASIS)</td>
<td>Randomized Open-label</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Antiphospholipid Antibodies and Stroke Study (APASS)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Aspirin and Carotid Endarterectomy Trial (ACE)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Endarterectomy</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Clopidogrel</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Netherlands Heart Foundation; the UK Stroke Association</td>
<td>European / Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT)</td>
<td>Randomized Open-label</td>
<td>Aspirin Dipyridamole Anticoagulants</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Boehringer-Ingelheim</td>
<td>European Stroke Prevention Study (ESPS-2)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS)</td>
<td>Phase IV Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Stroke Prevention in Atrial Fibrillation III (SPAF III)</td>
<td>Randomized</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Stroke Prevention in Reversible Ischemia Trial (SPIRIT)</td>
<td>Phase III Randomized Open-label</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>J. Uriach &amp; Cia S.A.</td>
<td>Triflusal vs Aspirin for the Prevention of Infarction: Randomized Stroke Study (TAPIRSS)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Trifusal</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Warfarin vs Aspirin Recurrent Stroke Study</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Anturane TIA Italian Study (ATIAIS)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Sulfinpyrazone</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>J. Uriach &amp; Cia, S.A.</td>
<td>Triflusal vs Acetylsalicylic Acid in Secondary Prevention of Cerebral Infarction (TACIP)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Trifusal</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Medical Research Council; Beecham Products; Eli Lilly; Evans Medical /Glaxo; Wasell Packaging; Aspirin Foundation</td>
<td>United Kingdom Transient Ischaemic Attack Aspirin Trial (UK-TIA)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK II)</td>
<td>Phase III Randomized</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Secondary Prevention of Small Subcortical Strokes Trial (SPS3)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Clopidogrel Antihypertensive</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>NINDS</td>
<td>Warfarin vs Aspirin in Reduced Cardiac Ejection Fraction Trial (WARCEF)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>Bundesministerium fur Forschung und Technologie (BMFT)</td>
<td>Carotid Artery Stenosis with Asymptomatic Narrowing: Operation vs Aspirin (CASANOVA)</td>
<td>Randomized</td>
<td>Aspirin Endarterectomy</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Heparin in Acute Embolic Stroke Trial (HAEST)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Dalteparin LMW heparin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Warfarin-Aspirin Symptomatic Intracranial Disease Study—Retrospective (WASID-R)</td>
<td>N/A</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NHLBI</td>
<td>Recurrent Carotid Stenosis</td>
<td>Phase II Randomized Double-Blind</td>
<td>Aspirin Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Netherlands Heart Foundation; Bayer; UK Stroke Association; University Hospitals of Utrecht and Rotterdam</td>
<td>European Atrial Fibrillation Trial (EAFT)</td>
<td>Randomized</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Danish Heart Foundation, Danish Insurance Association; Leo Pharmaceutical Products</td>
<td>Danish very-low-dose aspirin after carotid endarterectomy trial</td>
<td>Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Low-dose acetylsalicylic acid (ASA) plus dipyridamole vs dipyridamole alone in stroke prevention</td>
<td>Non-randomized</td>
<td>Aspirin Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Farmos Group, Sweden</td>
<td>Swedish Cooperative Study</td>
<td>Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Boehringer-Ingelheim</td>
<td>Persantine Aspirin Trial</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia (AICLA)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Medical Research Council of Canada</td>
<td>Aspirin and sulfinpyrazone in threatened stroke</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Sulfinpyrazone</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>NHLBI</td>
<td>Aspirin in Transient Ischemic Attacks (AITIA)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Danish Medical Research Council</td>
<td>Danish Cooperative Study</td>
<td>Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Dutch TIA Study (Dutch TIA)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Atenolol</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Sanofi-Synthelabo Recherche, France</td>
<td>Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischemic attack or ischemic stroke (MATCH)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Clopidogrel </td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Syntex Research, Palo Alto, CA</td>
<td>Ticlopidine Aspirin Stroke Study</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Ticlopidine</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Swedish National Association against Heart and Chest Diseases and Greta and Johan Koch's Foundation </td>
<td>Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks</td>
<td>Randomized</td>
<td>Aspirin Dipyridamole Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>United Laboratory &amp; Philippine Council for Health Research and Development</td>
<td>Aspirin Dose Optimized in Non-Cardioembolic Ischemic Stroke (ADONIS)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin </td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Asistance Publique - Hôpitaux de Paris; National Health and Medical Research Council, Australia; Sanofi-Aventis</td>
<td>Aortic Arch Related Cerebral Hazard Trial (ARCH)</td>
<td>Phase III Randomized Open-label</td>
<td>Aspirin Clopidogrel Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img3.tif"/>
</td>
</tr>
<tr>
<td>AGA Medical Corporation</td>
<td>RESPECT PFO Clinical Trial</td>
<td>Phase II Randomized Open-label</td>
<td>Aspirin Clopidogrel Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img3.tif"/>
</td>
</tr>
<tr>
<td>Canadian Stroke Consortium; Canadian Stroke Network; Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada; Ministry of Health and Long-Term Care Ontario; Merck Research Laboratories</td>
<td>Fast Assessment of Stroke and Transient ischemic attack to prevent Early Recurrence—Pilot Study (FASTER)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Clopidogrel Simvastatin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Sanofi-Aventis, Bristol Myers Squibb</td>
<td>Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Clopidogrel</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Sanofi-Aventis</td>
<td>Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) </td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Clopidogrel</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>The Netherlands National Health Insurance Fund Council</td>
<td>Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2)</td>
<td>Randomized Open-label</td>
<td>Aspirin Anticoagulants</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK I)</td>
<td>Randomized</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Ministry of Health, Labor and Welfare, Japan; Bayer; Japan Heart Foundation </td>
<td>Japanese Primary Prevention Project With Aspirin</td>
<td>Phase IV Randomized Open-label</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img3.tif"/>
</td>
</tr>
<tr>
<td>Cogentus Pharmaceuticals</td>
<td>Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Clopidogrel CGT-2168</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img4.tif"/>
</td>
</tr>
<tr>
<td>Medical Research Council</td>
<td>Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA)</td>
<td>Randomized</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Translational Research Informatics Center, Kobe, Hyogo, Japan; Tohoku University; China National Center for Cardiovascular Diseases </td>
<td>Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis</td>
<td>Phase III Randomized Open-label</td>
<td>Aspirin Cilostazol</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>Sanofi-Aventis, Bristol Myers Squibb</td>
<td>Clopidogrel and Aspirin vs Aspirin Alone in Stroke Patients (PLUTO)</td>
<td>Randomized</td>
<td>Aspirin Clopidogrel</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Assistance Publique - Hôpitaux de Paris; Sanofi-Synthelabo </td>
<td>Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Noncoronary Surgery (STRATAGEM)</td>
<td>Phase IV Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>N/A</td>
<td>Amplified Benefit of Clopidogrel vs Aspirin in Patients With Diabetes Mellitus</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Clopidogrel</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Spanish Society of Cardiology; Uriach Foundation</td>
<td>National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Mitsubishi Tanabe Pharma Corporation</td>
<td>Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Sarpogrelate</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Sanofi-Aventis, Bristol Myers Squibb</td>
<td>Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)</td>
<td>Phase III Randomized Open-label</td>
<td>Aspirin Clopidogrel Warfarin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img4.tif"/>
</td>
</tr>
<tr>
<td>Johnson and Johnson Corporation</td>
<td>Drug-Eluting Stents for the Treatment of Intracranial Atherosclerosis.</td>
<td>N/A</td>
<td>Aspirin Clopidogrel Carotid stenting</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>University of Oxford; Bayer; British Heart Foundation</td>
<td>A Study of Cardiovascular Events iN Diabetes (ASCEND)</td>
<td>Phase IV Randomized Double-Blind</td>
<td>Aspirin Omega-3 fatty acids</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>Asan Medical Center; Korea Otsuka International Asia Arab </td>
<td>Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II (TOSS-2)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Clopidogrel Cilostazol</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Boehringer-Ingelheim</td>
<td>Japanese Aggrenox Stroke Prevention vs Aspirin Programme (JASAP)</td>
<td>Phase III</td>
<td>Aspirin Aggrenox</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Bayer</td>
<td>A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Long Term Open Follow-up With H376/95 vs Warfarin</td>
<td>Phase II Randomized Open-label</td>
<td>Aspirin Clopidogrel EXANT</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img4.tif"/>
</td>
</tr>
<tr>
<td>Samsung Medical Center</td>
<td>The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol</td>
<td>Randomized Open-label</td>
<td>Aspirin Clopidogrel Cilostazol</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Otsuka Beijing Research Institute; Zhejiang Otsuka Pharmaceutical Co, Ltd</td>
<td>Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke (4C-DES)</td>
<td>Phase III Randomized Double-Blind</td>
<td>Aspirin Cilostazol</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>The George Institute; Byrraju Foundation; The Future Forum, UK</td>
<td>Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)</td>
<td>Randomized IV Randomized Open-label</td>
<td>Aspirin Atenolol Statin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>
</td>
</tr>
<tr>
<td>Kumamoto University</td>
<td>Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial (JPAD)</td>
<td>Randomized IV Randomized Double-Blind</td>
<td>Aspirin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>The Stroke Association (UK)</td>
<td>Dual antiplatelet therapy in the acute phase following stroke and transient ischemic attack (TIA): which is the best regimen? (AMBDAP)</td>
<td>Randomized Double-Blind</td>
<td>Aspirin Clopidogrel Dipyridamole</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
<tr>
<td>Peking Union Medical College Hospital</td>
<td>Standard Medical Management in Secondary Prevention of Ischemic Stroke in China (SMART)</td>
<td>Randomized Open-label</td>
<td>Aspirin Clopidogrel Atovastatin</td>
<td>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029612449197">
<p>
<inline-graphic xlink:href="10.1177_1076029612449197-img1.tif"/>: Completed; <inline-graphic xlink:href="10.1177_1076029612449197-img2.tif"/>: Active, but not recruiting; <inline-graphic xlink:href="10.1177_1076029612449197-img4.tif"/>: Terminated; <inline-graphic xlink:href="10.1177_1076029612449197-img3.tif"/>: Active recruitment</p>
<p>Source: http://www.strokecenter.org/trials/interventions</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-1076029612449197">
<title>Bleeding Complications Due to the Use of Aspirin</title>
<p>In recent decades, aspirin has been the most-prescribed component of antiplatelet therapy for primary or secondary prevention of MI and acute ischemic stroke (AIS). However, aspirin regimen with a therapeutic effect as an antiplatelet agent vis-à-vis its bleeding complication has been of great interest among cardiologists, stroke neurologists and primary care physicians. Inhibition of cyclooxygenase 1 (COX-1), and subsequently prostaglandin, by aspirin can result in damage to the upper gastrointestinal (GI) mucosa.<sup>
<xref ref-type="bibr" rid="bibr5-1076029612449197">5</xref>
</sup> Several studies have demonstrated increased risk of upper GI complications at higher daily doses of aspirin.<sup>
<xref ref-type="bibr" rid="bibr6-1076029612449197">6</xref>
</sup> In a clinical trial, 2435 patients with TIA or AIS were randomly assigned to receive 600 mg aspirin twice daily, 300 mg aspirin once daily, or a placebo.<sup>
<xref ref-type="bibr" rid="bibr7-1076029612449197">7</xref>
</sup> The study found no difference in efficacy between 300 and 1200 mg doses of aspirin, while the lower dose led to less GI complications such as bleeding. A meta-analysis of 287 randomized trials published by Antithrombotic Trialists’ Collaboration showed that a low daily dose of aspirin (75-150 mg) was as effective as a higher dose of an antiplatelet regimen for the prevention of vascular events such as nonfatal MI, nonfatal stroke, or vascular death.<sup>
<xref ref-type="bibr" rid="bibr8-1076029612449197">8</xref>
</sup> The same outcomes were confirmed by a systemic analysis of 31 clinical trials with a total of 192 036 patients, which suggested that the daily use of low dose aspirin (&lt;100 mg) was associated with the lowest risk of GI and intracranial bleeding, when compared with a moderate (100-200 mg) and high (&gt;200 mg) dose of aspirin.<sup>
<xref ref-type="bibr" rid="bibr6-1076029612449197">6</xref>
</sup>
</p>
</sec>
<sec id="section5-1076029612449197">
<title>Aspirin Resistance</title>
<p>Individuals taking aspirin but who fail to appropriately respond to the medication may remain at higher risk of cerebrovascular events. The term “aspirin resistance” or “aspirin nonresponse” has no standard accepted definition in the literature. The definition should be pharmacologically based on the inability of a drug to reach its target as a consequence of reduced bioavailability, in vivo inactivation, or negative interaction.<sup>
<xref ref-type="bibr" rid="bibr9-1076029612449197">9</xref>
</sup> However, the determination has variably been based on the occurrence of a vascular event while on aspirin (clinical aspirin resistance) versus laboratory findings (laboratory aspirin resistance).<sup>
<xref ref-type="bibr" rid="bibr10-1076029612449197">10</xref>
</sup>
</p>
<p>The lack of a clear definition has resulted in conflicting published reports on the prevalence and outcome of aspirin as an antiplatelet therapy for cardiovascular, cerebrovascular, and peripheral vascular diseases (PVD).<sup>
<xref ref-type="bibr" rid="bibr11-1076029612449197">11</xref>
<xref ref-type="bibr" rid="bibr12-1076029612449197"/>
<xref ref-type="bibr" rid="bibr13-1076029612449197"/>
<xref ref-type="bibr" rid="bibr14-1076029612449197"/>
<xref ref-type="bibr" rid="bibr15-1076029612449197"/>
<xref ref-type="bibr" rid="bibr16-1076029612449197"/>
<xref ref-type="bibr" rid="bibr17-1076029612449197"/>
<xref ref-type="bibr" rid="bibr18-1076029612449197"/>
<xref ref-type="bibr" rid="bibr19-1076029612449197"/>
<xref ref-type="bibr" rid="bibr20-1076029612449197"/>
<xref ref-type="bibr" rid="bibr21-1076029612449197"/>
<xref ref-type="bibr" rid="bibr22-1076029612449197"/>
<xref ref-type="bibr" rid="bibr23-1076029612449197"/>
<xref ref-type="bibr" rid="bibr24-1076029612449197"/>
<xref ref-type="bibr" rid="bibr25-1076029612449197"/>
<xref ref-type="bibr" rid="bibr26-1076029612449197"/>
<xref ref-type="bibr" rid="bibr27-1076029612449197"/>
<xref ref-type="bibr" rid="bibr28-1076029612449197"/>–<xref ref-type="bibr" rid="bibr29-1076029612449197">29</xref>
</sup> There is not much data on the prevalence of aspirin resistance in generally healthy participants. In patients with various vascular diseases, the rate of nonresponders reported varies between &lt;2% to &gt;60%. In a systematic review of aspirin resistance studies, the mean prevalence was 24%.<sup>
<xref ref-type="bibr" rid="bibr30-1076029612449197">30</xref>
</sup> Some studies have reported as high as 30% to 40% of nonresponders among stroke or vascular disease patients and a predicted &gt;80% increase risk of a repeat vascular event during a 2-year follow-up period.<sup>
<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>
<xref ref-type="bibr" rid="bibr13-1076029612449197"/>–<xref ref-type="bibr" rid="bibr14-1076029612449197">14</xref>,<xref ref-type="bibr" rid="bibr20-1076029612449197">20</xref>
</sup> Since the methods used to monitor aspirin resistance in these reports are not specific, the published prevalence rates are debatable.<sup>
<xref ref-type="bibr" rid="bibr11-1076029612449197">11</xref>
<xref ref-type="bibr" rid="bibr12-1076029612449197"/>
<xref ref-type="bibr" rid="bibr13-1076029612449197"/>
<xref ref-type="bibr" rid="bibr14-1076029612449197"/>
<xref ref-type="bibr" rid="bibr15-1076029612449197"/>
<xref ref-type="bibr" rid="bibr16-1076029612449197"/>
<xref ref-type="bibr" rid="bibr17-1076029612449197"/>
<xref ref-type="bibr" rid="bibr18-1076029612449197"/>
<xref ref-type="bibr" rid="bibr19-1076029612449197"/>
<xref ref-type="bibr" rid="bibr20-1076029612449197"/>
<xref ref-type="bibr" rid="bibr21-1076029612449197"/>
<xref ref-type="bibr" rid="bibr22-1076029612449197"/>
<xref ref-type="bibr" rid="bibr23-1076029612449197"/>
<xref ref-type="bibr" rid="bibr24-1076029612449197"/>
<xref ref-type="bibr" rid="bibr25-1076029612449197"/>
<xref ref-type="bibr" rid="bibr26-1076029612449197"/>
<xref ref-type="bibr" rid="bibr27-1076029612449197"/>
<xref ref-type="bibr" rid="bibr28-1076029612449197"/>–<xref ref-type="bibr" rid="bibr29-1076029612449197">29</xref>
</sup>
</p>
</sec>
<sec id="section6-1076029612449197">
<title>Clinical Aspirin Resistance</title>
<p>Clinical manifestation of aspirin resistance is defined as occurrence of acute vascular events such as MI, stroke, or PAD in patients despite aspirin prophylaxis. This may also be called “treatment failure.”<sup>
<xref ref-type="bibr" rid="bibr9-1076029612449197">9</xref>,<xref ref-type="bibr" rid="bibr31-1076029612449197">31</xref>
</sup> In the literature, it is suggested that there is an association between clinical aspirin resistance and an increased risk of vascular events.<sup>
<xref ref-type="bibr" rid="bibr32-1076029612449197">32</xref>
<xref ref-type="bibr" rid="bibr33-1076029612449197"/>
<xref ref-type="bibr" rid="bibr34-1076029612449197"/>–<xref ref-type="bibr" rid="bibr35-1076029612449197">35</xref>
</sup> However, in a post hoc analysis of the data from the National Institute of Neurological Disorders and Stroke intravenous recombinant tissue plasminogen activator trial and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST), aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.<sup>
<xref ref-type="bibr" rid="bibr36-1076029612449197">36</xref>
</sup> The difficulty with a clinical definition is due to the implication that all acute vascular events occurring while the patient is on aspirin could have been prevented with proper response to the drug. However, aspirin inhibits only 1 pathway in platelet function and thus even an appropriate response to aspirin may not completely prevent such events from occurring.</p>
</sec>
<sec id="section7-1076029612449197">
<title>Laboratory Aspirin Resistance</title>
<p>The laboratory observation of aspirin resistance definitions have ranged from the specific failure to inhibit thromboxane A<sub>2</sub> (TXA<sub>2</sub>), failure to inhibit a test of platelet function that is dependent on TXA<sub>2</sub> production, and the very broad failure to inhibit 1 or more platelet function assays.<sup>
<xref ref-type="bibr" rid="bibr9-1076029612449197">9</xref>,<xref ref-type="bibr" rid="bibr31-1076029612449197">31</xref>,<xref ref-type="bibr" rid="bibr37-1076029612449197">37</xref>,<xref ref-type="bibr" rid="bibr38-1076029612449197">38</xref>
</sup> The methods can predominately be divided into assays that assess the effect of aspirin on a functional platelet response and assays that measure metabolites downstream from COX-1. Studies have used single or various combinations of assays with a wide range of cutoff points for the determination of responder and nonresponder status.</p>
<p>For the purposes of this review, aspirin resistance is defined as the failure to inhibit either platelet function or production of a thromboxane metabolite in a laboratory study (ie, insufficient blockage of platelet reactivity despite aspirin therapy in an in vitro setting). A laboratory definition is preferred as ideally it would be desirable to be able to use testing to predict who may be at higher risk to have a vascular event while on aspirin so that measures can be taken to hopefully prevent an event that would meet the definition of clinical resistance. As the best test or combination of tests for the measurement of laboratory resistance has yet to be established, familiarity with the commonly used methods is pertinent.</p>
<p>Light transmittance aggregometry (LTA) measures the amount of light that passes through a platelet suspension as platelet aggregation occurs in response to an agonist. LTA is labor intensive, requires a large specimen volume, and is poorly standardized between laboratories. A variety of agonists such as arachidonic acid (AA), adenosine diphosphate (ADP), and epinephrine have been used at different concentrations and with diverse cutoff points to categorize individuals as aspirin resistant. Studies in our laboratory over 3 decades have failed to show any aspirin resistance in normal healthy participants. The only participant whose platelets failed to aggregate in response to AA stimulation was found to be deficient in platelet COX-1 enzyme activity.<sup>
<xref ref-type="bibr" rid="bibr39-1076029612449197">39</xref>
</sup> Platelets obtained from this participant responded with aggregation when stirred with epinephrine and arachidonate, suggesting prostaglandin endoperoxides and TXA<sub>2</sub> are not essential to cause irreversible aggregation of platelets. Aspirin resistance by LTA has been associated with an increase in adverse events. Gum et al<sup>
<xref ref-type="bibr" rid="bibr15-1076029612449197">15</xref>
</sup> studied aspirin sensitivity by platelet response to aggregating agents such as ADP and AA among stable cardiovascular participants (n = 326) on aspirin (325 mg/day). They found that 5.5% were nonresponders to aspirin and 24% were semiresponders by platelet aggregation, in comparison 9.5% were nonresponders by Platelet Function Analyzer-100 (PFA-100; Siemens Healthcare Diagnostics, Deerfield, Illinois). In a follow-up study of these participants,<sup>
<xref ref-type="bibr" rid="bibr16-1076029612449197">16</xref>
</sup> aspirin resistance was found to be associated with an increased risk of death, MI, or cerebrovascular accident.</p>
<p>Whole blood aggregometry (WBA) or multiple electrode aggregometry (MEA) uses electrical impedance to measure platelet aggregation. The use of whole blood decreases the amount of sample processing compared with LTA; however, this test also remains labor intensive and requires a large specimen volume. A study<sup>
<xref ref-type="bibr" rid="bibr20-1076029612449197">20</xref>
</sup> conducted in Austria assessed platelet function by WBA of patients undergoing arterial angioplasty while on 100 mg aspirin per day. This study demonstrated that reocclusion at the sites of angioplasty occurred only in men for whom platelet dysfunction was evident by aggregometry.</p>
<p>The PFA-100 measures platelet aggregation by running whole blood under shear stress through a membrane with an opening coated with collagen/epinephrine or collagen/ADP and measuring the time to closure of the opening. The test is easy to operate; however, the PFA-100 is sensitive to multiple variables other than aspirin, including the von Willebrand factor, platelet count, and hematocrit.<sup>
<xref ref-type="bibr" rid="bibr40-1076029612449197">40</xref>
<xref ref-type="bibr" rid="bibr41-1076029612449197"/>
<xref ref-type="bibr" rid="bibr42-1076029612449197"/>–<xref ref-type="bibr" rid="bibr43-1076029612449197">43</xref>
</sup> In a retrospective study of aspirin for secondary prevention of vascular events, Grundmann et al<sup>
<xref ref-type="bibr" rid="bibr44-1076029612449197">44</xref>
</sup> observed a 34% nonresponder rate in symptomatic individuals with an event within the last 3 days. Bugnicourt et al<sup>
<xref ref-type="bibr" rid="bibr45-1076029612449197">45</xref>
</sup> found an increased rate of early neurological deterioration in patients with AIS on 160 mg aspirin daily in nonresponders by collagen/epinephrine PFA-100 testing compared with responders.</p>
<p>The VerifyNow Aspirin assay (Accumetrics, San Diego, California) measures the agglutination of fibrinogen coated beads with the patient’s platelets in response to the agonist AA. The result is reported in aspirin response units. The test is an easy to use whole blood point-of-care test. Chen et al<sup>
<xref ref-type="bibr" rid="bibr46-1076029612449197">46</xref>
</sup> found a rate of aspirin resistance rate of 27.4% in patients with stable coronary artery disease. Patients with aspirin resistance had a higher rate of a composite cardiovascular end point (15.6% vs 5.3% hazard ratio).</p>
<p>Plateletworks (Helena Laboratories, Beaumont, Texas) is another modification of platelet aggregation test. The test compares the platelet count in whole blood as measured by impedance in nonagonist control and agonist containing tubes. The difference in platelet count reflects the degree of aggregation and is used to calculate the percentage aggregation. The method is quick and simple use; however, there is little experience with this approach. Hurlen et al<sup>
<xref ref-type="bibr" rid="bibr19-1076029612449197">19</xref>
</sup> used the related method of Wu and Hoak<sup>
<xref ref-type="bibr" rid="bibr27-1076029612449197">27</xref>
</sup> to determine the platelet aggregation ratio as a marker for assessing platelet function and evaluated the effect of aspirin (160 mg/d) in 143 patients who had survived MI. Based on their definition of nonresponders to the action of aspirin, they could only identify 2 participants as primary nonresponders.</p>
<p>Thromboelastography (TEG; Haemoscope Corporation, Niles, Illinois) is a viscoelastic whole blood test that measures clot formation in response to thrombin generation. A further modification of this test, the TEG Platelet Mapping system (Haemoscope Corporation), assesses platelet inhibition by comparing the maximum amplitude of clot strength from a standard TEG and reactions activated with reptilase and factor XIII with and without the addition of AA or ADP. A study of patients undergoing coronary artery bypass grafting (CABG) demonstrated a 30% rate of aspirin resistance based on positive findings with at least 2 of the following tests: TEG Platelet Mapping, WBA, or 11-dehydro-thromboxane B<sub>2</sub>.<sup>
<xref ref-type="bibr" rid="bibr47-1076029612449197">47</xref>
</sup> Nonresponders had a higher rate of graft thrombosis compared with responders (45% vs 20%, <italic>P</italic> &lt; .05). Tantry et al<sup>
<xref ref-type="bibr" rid="bibr48-1076029612449197">48</xref>
</sup> found a much lower rate of only 1 in 223 patients undergoing percutaneous intervention or history of stent thrombosis based on TEG Platelet Mapping and LTA.</p>
<p>Serum thromboxane B<sub>2</sub> (TXB<sub>2</sub>) is a stable metabolite of thomboxane A<sub>2</sub> (TXA<sub>2</sub>). Aspirin inhibits COX-1 activity resulting in decreased TXA<sub>2</sub> production, which leads to lower levels of TXA<sub>2</sub> metabolites. TXB<sub>2</sub> has been proposed as the most specific biochemical marker for aspirin.<sup>
<xref ref-type="bibr" rid="bibr10-1076029612449197">10</xref>,<xref ref-type="bibr" rid="bibr49-1076029612449197">49</xref>
<xref ref-type="bibr" rid="bibr50-1076029612449197"/>–<xref ref-type="bibr" rid="bibr51-1076029612449197">51</xref>
</sup> The rate of aspirin resistance is quite low based on serum TXB<sub>2</sub>. Frelinger et al<sup>
<xref ref-type="bibr" rid="bibr52-1076029612449197">52</xref>
</sup> observed a rate of only 2 in 682 participants treated with aspirin that presented for cardiac catheterization who had serum TXB<sub>2</sub> levels in the range of nontreated individuals; however, it was not established if this reflected noncompliance or nonresponse. Based on receiver–operator characteristic analysis, a serum TXB<sub>2</sub> level of &gt;3.1 ng/mL was associated with increased risk of major adverse cardiovascular events.</p>
<p>Yet another test, urinary 11-dehydro thromboxane B<sub>2</sub> (11-DTB<sub>2</sub>), may offer an advantage over the other assays. The 11-DTB<sub>2</sub> is a stable metabolite of TXA<sub>2</sub>.<sup>
<xref ref-type="bibr" rid="bibr53-1076029612449197">53</xref>,<xref ref-type="bibr" rid="bibr54-1076029612449197">54</xref>
</sup> It can be measured using the FDA approved AspirinWorks test (Corgenix, Broomfield, Colorado). Testing can be performed on stored urine samples, which has logistical advantages for research studies. Urinary 11-DTB<sub>2</sub> includes both platelet and nonplatelet sources. Monitoring stable metabolites of TXA<sub>2</sub>, such as 11-DTB<sub>2</sub>, has been performed among patients with history of vascular disease and stroke.<sup>
<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>,<xref ref-type="bibr" rid="bibr32-1076029612449197">32</xref>,<xref ref-type="bibr" rid="bibr55-1076029612449197">55</xref>
<xref ref-type="bibr" rid="bibr56-1076029612449197"/>
<xref ref-type="bibr" rid="bibr57-1076029612449197"/>
<xref ref-type="bibr" rid="bibr58-1076029612449197"/>
<xref ref-type="bibr" rid="bibr59-1076029612449197"/>
<xref ref-type="bibr" rid="bibr60-1076029612449197"/>
<xref ref-type="bibr" rid="bibr61-1076029612449197"/>–<xref ref-type="bibr" rid="bibr62-1076029612449197">62</xref>
</sup> Bruno et al<sup>
<xref ref-type="bibr" rid="bibr56-1076029612449197">56</xref>
</sup> published the results of urinary 11-DTB<sub>2</sub> of 87 African American participants within 4 months of a noncardioembolic ischemic stroke. The study suggested a significant independent effect of aspirin on urinary 11-DTB<sub>2</sub> levels regardless of the aspirin dose (between 325 and 1300 mg daily). In a follow-up study conducted by the same group,<sup>
<xref ref-type="bibr" rid="bibr55-1076029612449197">55</xref>
</sup> the investigators concluded that the fluctuations in urinary 11-DTB<sub>2</sub> level were not correlated with changes in aspirin dose. However, in both the studies, underpowered sample size had been mentioned as among the shortcomings of the studies. Eikelboom et al<sup>
<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>
</sup> analyzed baseline urinary 11-DTB<sub>2</sub> in 5529 patients enrolled in the Heart Outcomes Prevention Evaluation (HOPE) study. Of these patients, 488 were on aspirin regimen. On the basis of their findings, they concluded that in aspirin-treated patients, increased levels of urinary 11-DTB<sub>2</sub> predicted future risk of MI or cardiovascular death. The patients with the highest levels of urinary 11-DTB<sub>2</sub> had 3- to 5-fold higher risk of cardiovascular death compared with those in the lowest quartile.</p>
<p>The detection of aspirin resistance is greatly influenced by the method and cutoff point. Several studies have used multiple methods to look for aspirin resistance and have found large differences between methods. The prevalence of aspirin resistance is also dependent on the dose<sup>
<xref ref-type="bibr" rid="bibr63-1076029612449197">63</xref>,<xref ref-type="bibr" rid="bibr64-1076029612449197">64</xref>
</sup> and timing<sup>
<xref ref-type="bibr" rid="bibr65-1076029612449197">65</xref>
</sup> of aspirin therapy. Lordkipanidze et al<sup>
<xref ref-type="bibr" rid="bibr66-1076029612449197">66</xref>
</sup> compared 6 methods for detecting aspirin resistance in 201 patients with stable coronary artery disease. They observed poor correlation between assays and a wide range in prevalence according to the assay: 4% LTA with AA, 10.3% to 51.7% LTA with ADP, 6.75% with VerifyNow Aspirin, 18.0% withWBA, and 59.5% with PFA-100. Grove et al<sup>
<xref ref-type="bibr" rid="bibr50-1076029612449197">50</xref>
</sup> used 6 methods (LTA with AA, MEA, PFA-100, VerifyNow Aspirin, urinary 11-DTB<sub>2</sub>, and serum TXB<sub>2</sub>). The study found poor correlation between the methods, no correlation between urinary 11-DTB<sub>2</sub> and the 4 platelet function tests, and serum TXB<sub>2</sub> correlated only with VerifyNow Aspirin. Six participants were nonresponders by LTA, only 2 of which were nonresponders by another method, PFA-100. Sane et al<sup>
<xref ref-type="bibr" rid="bibr24-1076029612449197">24</xref>
</sup> evaluated the effect of aspirin (325 mg/d per month) in patients suffering from congestive heart failure by multiple methods. A participant was considered a non-responder when 4 of the following 5 parameters were observed: collagen-induced aggregation &gt;70%, ADP induced aggregation &gt;60%, whole blood aggregation &gt;18 ohms, expression of active glycoprotein (GP) IIb/IIIa&gt;220 log mean fluorescence intensity units, and P-selectin positivity &gt;8%. Using this complex rating, persistent platelet activation was observed in 50 of the 88 patients (56.8%). However, when participants were grouped into aspirin nonresponders and aspirin responders based on this system, only 3 of these variables, ADP induced aggregation, expression of active GP IIb/IIIa, and P-selectin positivity, were statistically different among the 2 groups. A number of other variables were tested in the 2 groups by PFA-100 testing and flow cytometry with a significant difference found only with GP IIb/IIIa activity, GP Ib, platelet-endothelia cell tetra span antigen (CD151), and platelet leukocyte aggregates (CD151 and CD14).</p>
<p>The timing of testing must also be considered when evaluating for aspirin resistance. Henry et al<sup>
<xref ref-type="bibr" rid="bibr65-1076029612449197">65</xref>
</sup> observed that once daily dosing of aspirin did not prevent platelet aggregation for a full 24-hour significant platelet aggregation appeared before the next dose of aspirin. Zimmerman et al<sup>
<xref ref-type="bibr" rid="bibr29-1076029612449197">29</xref>
</sup> identified aspirin nonresponders as those who had &gt;90% inhibition of TXA<sub>2</sub> formation in the presence of 100 μmol/L aspirin and 1 mmol/L arachidonate in the supernatant from platelet aggregation. In patients who had undergone CABG, AA- and collagen-stimulated formation of TXB<sub>2</sub> was the same before and after CABG, indicating oral aspirin did not significantly inhibit platelet COX-1. However, the in vitro studies with 100 μmol/L aspirin on blood obtained from these participants showed decreased TXB<sub>2</sub> (&gt;10%) in most samples studied. They concluded that platelet COX-1 inhibition by aspirin is compromised for several days after CABG, probably due to an impaired interaction between aspirin and platelet COX-1. This observation indicates how complex the issues are when evaluating the effect of antiplatelet drugs during and after interventional procedures.</p>
<p>These observations remind us of the inadequacy of the existing methods to detect what truly represents “aspirin resistance.” Moreover, studies from our laboratory have demonstrated that platelets exposed to aspirin will respond with aggregation when stirred with prostaglandin endoperoxides or thromboxane (the bioactive metabolites of AA).<sup>
<xref ref-type="bibr" rid="bibr67-1076029612449197">67</xref>
<xref ref-type="bibr" rid="bibr68-1076029612449197"/>
<xref ref-type="bibr" rid="bibr69-1076029612449197"/>–<xref ref-type="bibr" rid="bibr70-1076029612449197">70</xref>
</sup> Therefore, as long as these bioactive molecules are available in the circulation regardless of their source, there exists a certain risk of developing acute vascular events leading to MI or stroke. Because of the differences in methodologies used to monitor this phenomenon and the lack of a specific assay to determine true aspirin resistance, there is considerable confusion and the true significance of this observation remains obscure.<sup>
<xref ref-type="bibr" rid="bibr15-1076029612449197">15</xref>,<xref ref-type="bibr" rid="bibr18-1076029612449197">18</xref>,<xref ref-type="bibr" rid="bibr19-1076029612449197">19</xref>,<xref ref-type="bibr" rid="bibr22-1076029612449197">22</xref>,<xref ref-type="bibr" rid="bibr26-1076029612449197">26</xref>
<xref ref-type="bibr" rid="bibr27-1076029612449197"/>–<xref ref-type="bibr" rid="bibr28-1076029612449197">28</xref>,<xref ref-type="bibr" rid="bibr71-1076029612449197">71</xref>
<xref ref-type="bibr" rid="bibr72-1076029612449197"/>
<xref ref-type="bibr" rid="bibr73-1076029612449197"/>
<xref ref-type="bibr" rid="bibr74-1076029612449197"/>
<xref ref-type="bibr" rid="bibr75-1076029612449197"/>
<xref ref-type="bibr" rid="bibr76-1076029612449197"/>
<xref ref-type="bibr" rid="bibr77-1076029612449197"/>
<xref ref-type="bibr" rid="bibr78-1076029612449197"/>–<xref ref-type="bibr" rid="bibr79-1076029612449197">79</xref>
</sup> It also raises the question of how we have missed this phenomenon of drug resistance for so long. Large numbers of clinical trials have demonstrated the beneficial effects of aspirin therapy regardless of the disease state. It is hard to imagine that these earlier trials missed aspirin nonresponders. On the other hand, it is quite possible that only responders to the action of aspirin received the therapeutic benefit.</p>
</sec>
<sec id="section8-1076029612449197">
<title>Aspirin Therapy Compliance for the Prevention of Stroke</title>
<p>While compliance with antiplatelet therapy for prevention of stroke is essential, patient adherence to any long-term therapy, including aspirin, has been always a challenge for treating physicians. This is particularly an issue among the elderly population with a history of stroke or MI facing memory impairment or depression, as they have the highest noncompliance rate observed within the first year of the therapy.<sup>
<xref ref-type="bibr" rid="bibr80-1076029612449197">80</xref>
<xref ref-type="bibr" rid="bibr81-1076029612449197"/>
<xref ref-type="bibr" rid="bibr82-1076029612449197"/>
<xref ref-type="bibr" rid="bibr83-1076029612449197"/>
<xref ref-type="bibr" rid="bibr84-1076029612449197"/>–<xref ref-type="bibr" rid="bibr85-1076029612449197">85</xref>
</sup> Upper GI complications due to the use of aspirin can be another underlying cause of noncompliance.<sup>
<xref ref-type="bibr" rid="bibr86-1076029612449197">86</xref>
</sup> Therefore, lack of compliance can be a significant contributing factor to the failure of aspirin therapy that on many occasions are mistakenly labeled as an “aspirin resistance” or “aspirin nonresponder” case. Cuisset et al<sup>
<xref ref-type="bibr" rid="bibr87-1076029612449197">87</xref>
</sup> found that 19 (14%) of 136 patients at 1 month after undergoing coronary stenting were nonresponders. Following observed aspirin ingestion, only 1 of the 19 patients was still found to be nonresponsive. Schwartz et al<sup>
<xref ref-type="bibr" rid="bibr88-1076029612449197">88</xref>
</sup> and Cotter et al<sup>
<xref ref-type="bibr" rid="bibr89-1076029612449197">89</xref>
</sup> observed similar findings. Studies that have not considered noncompliance factor may have overestimated the rate of aspirin resistance. TXB<sub>2</sub> can potentially be used as a marker of compliance<sup>
<xref ref-type="bibr" rid="bibr10-1076029612449197">10</xref>,<xref ref-type="bibr" rid="bibr49-1076029612449197">49</xref>
<xref ref-type="bibr" rid="bibr50-1076029612449197"/>–<xref ref-type="bibr" rid="bibr51-1076029612449197">51</xref>
</sup>; however, even with testing for TXB<sub>2</sub> levels, some individuals are classified as aspirin resistant. Although challenging, this warrants the need for establishing a reliable assessment method for gauging true proportion of noncompliant patients.</p>
</sec>
<sec id="section9-1076029612449197">
<title>Discussion</title>
<p>There are several contributing factors to aspirin resistance including aspirin dose, disease severity, genetic factors, inflammation, diabetes mellitus, non-COX-1–mediated TXA<sub>2</sub> synthesis, hyperlipidemia, smoking, and interacting drugs, especially nonsteroidal anti-inflammatory drugs (NSAIDs).<sup>
<xref ref-type="bibr" rid="bibr90-1076029612449197">90</xref>,<xref ref-type="bibr" rid="bibr91-1076029612449197">91</xref>
</sup> There have also been some reports revealing decreased inhibition of platelet aggregation by aspirin in the female population.<sup>
<xref ref-type="bibr" rid="bibr92-1076029612449197">92</xref>
</sup> In view of these observations, it is necessary to develop a multicenter study to look at the prevalence of at-risk population in patients undergoing antiplatelet therapy. It is important to monitor in vitro platelet function to evaluate the state of global hemostasis (combine activation of platelets and coagulation pathways) balance, in patients predisposed to hemorrhagic conditions. The decision to start antiplatelet therapy should be custom tailored based on individualized patient characteristics such as medical history and risk profile to increase the benefit of prevention strategy vis-à-vis serious adverse effects. In many cases of failure of aspirin therapy, it is not clear whether the underlying cause is nonresponse or noncompliance to aspirin therapy. However, a large portion of these cases are bundled into the nonrespondent group without proper investigation,<sup>
<xref ref-type="bibr" rid="bibr88-1076029612449197">88</xref>,<xref ref-type="bibr" rid="bibr93-1076029612449197">93</xref>
</sup> leading to a strong possibility that many of these cases may not be due to an inadequate platelet response to aspirin.<sup>
<xref ref-type="bibr" rid="bibr94-1076029612449197">94</xref>
</sup> Furthermore, in many published studies, nonresponders are grouped together based on platelet function assessments.</p>
<p>Platelet function tests are not specific for aspirin-dependent inhibition of COX-1 and resulting TXA<sub>2</sub> production because platelet adhesion can be mediated by other pathways (eg, ADP, thrombin, von Willebrand factor, and endothelial shear stress).<sup>
<xref ref-type="bibr" rid="bibr95-1076029612449197">95</xref>
</sup> Several recent studies have demonstrated that despite the inhibition of platelet COX-1 enzymes, a significant number of patients on aspirin prophylaxis had increased levels of urinary 11-DTB<sub>2</sub>.<sup>
<xref ref-type="bibr" rid="bibr11-1076029612449197">11</xref>,<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>
</sup> One possible explanation for this are the nonplatelet origins of TXA<sub>2</sub> such as monocytes, macrophages, and endothelial cells within atherosclerotic plaques.<sup>
<xref ref-type="bibr" rid="bibr37-1076029612449197">37</xref>
</sup> Regardless of the source of TXA<sub>2</sub>, what is clear from these studies is that those patients with an excess of urinary 11-DTB<sub>2</sub> are at risk of developing acute vascular events.<sup>
<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>,<xref ref-type="bibr" rid="bibr32-1076029612449197">32</xref>,<xref ref-type="bibr" rid="bibr60-1076029612449197">60</xref>
</sup> These observations from health care providers and researchers raise a number of concerns such as our true understanding of aspirin resistance phenomena, the prevalence of aspirin resistance in the healthy population, the causes of aspirin resistance in populations with history of vascular disease, the alternative long-term treatments for patients resistant to common antiplatelet therapies such as aspirin and clopidogrel and the appropriate dose escalation and availability of point-of-care tests that are specific and cost-effective. These concerns also raise the need to develop newer and more effective antiplatelet drugs.</p>
<p>It is worthwhile to emphasize that the multipathway mechanism of platelet activation requires multimode antiplatelet therapy in many cases. Platelet TXA<sub>2</sub> production through COX-2 that is not inhabited by aspirin or residual TXA<sub>2</sub> that may have a synergistic effect on collagen activated platelets is a factors that is needed to be considered.<sup>
<xref ref-type="bibr" rid="bibr96-1076029612449197">96</xref>
</sup>
</p>
<p>In our earlier published articles,<sup>
<xref ref-type="bibr" rid="bibr67-1076029612449197">67</xref>
<xref ref-type="bibr" rid="bibr68-1076029612449197"/>
<xref ref-type="bibr" rid="bibr69-1076029612449197"/>–<xref ref-type="bibr" rid="bibr70-1076029612449197">70</xref>,<xref ref-type="bibr" rid="bibr97-1076029612449197">97</xref>
</sup> we described how epinephrine-mediated membrane modulation restores the response of COX-1 deficient platelets and those of aspirin-exposed platelets to the action of agonists such as AA, ADP, and thrombin, independent of bioactive metabolites of AA. We also demonstrated that small quantities of endoperoxides or thromboxane generated from platelets or from some other sources could also cause aggregation of aspirin-exposed platelets. The half-life of aspirin in circulation is relatively short, and once the liver metabolizes it, the circulating salicylic acid has no inhibitory effect on platelet function. In addition, the bone marrow continuously produces fresh platelets and releases them into the blood. These newly released platelets contribute significantly to the thromboxane circulating in vivo.</p>
<p>In the HOPE study in which over 5500 patients were enrolled, it was found that in aspirin-treated participants, increased levels of urinary 11-DTB<sub>2</sub> predicted a future risk of MI and cardiovascular death.<sup>
<xref ref-type="bibr" rid="bibr11-1076029612449197">11</xref>,<xref ref-type="bibr" rid="bibr12-1076029612449197">12</xref>
</sup> The patients with the highest levels of urinary 11-DTB<sub>2</sub> had a 3- to 5-fold higher risk of cardiovascular death than those in the lowest quartile. The observed excess of in vivo thromboxane production may be due to an insufficient dose of aspirin in these participants, a lack of compliance, an excess production of new platelets from the bone marrow, or an altered or accelerated aspirin metabolism by these individuals. However, what is evident from recent studies is that no matter the source of this thromboxane, it puts the patients at risk of developing acute vascular events.<sup>
<xref ref-type="bibr" rid="bibr11-1076029612449197">11</xref>
<xref ref-type="bibr" rid="bibr12-1076029612449197"/>
<xref ref-type="bibr" rid="bibr13-1076029612449197"/>
<xref ref-type="bibr" rid="bibr14-1076029612449197"/>
<xref ref-type="bibr" rid="bibr15-1076029612449197"/>–<xref ref-type="bibr" rid="bibr16-1076029612449197">16</xref>
</sup>
</p>
<p>In light of the fact that the normal hemostasis is to a great extent modulated by the vasoactive metabolites of AA, thromboxane generated from platelets and prostacyclin (PGI<sub>2</sub>) produced by endothelial cells, the urinary metabolites of PGI<sub>2</sub> can also be measured.<sup>
<xref ref-type="bibr" rid="bibr60-1076029612449197">60</xref>
</sup> Therefore, it is recommended to monitor the levels of these vasoactive molecules. This need has been well demonstrated in studies regarding NSAIDs, where the investigators tested the hypotheses that adverse cardiovascular events reported among Anti-inflammatory Prevention Trial participants were associated with increased ratio of urinary 11-DTB<sub>2</sub> to 2′,3-donor-6-keto-PGF1 (PGI) attributable to NSAID treatments.<sup>
<xref ref-type="bibr" rid="bibr60-1076029612449197">60</xref>
</sup> Results of these studies showed that adverse cardiovascular events were significantly associated with higher urinary 11-DTB<sub>2</sub>/PGI ratio, which seemed to derive mainly from lowered PGI.</p>
<p>Moreover, the issue of noncompliance with antiplatelet treatment deserves special attention.<sup>
<xref ref-type="bibr" rid="bibr98-1076029612449197">98</xref>
</sup> Compliance should be confirmed before platelet function-based assays, such as LTA, PFA-100, and VerifyNow, which are used to evaluate aspirin response. A ratio of serum TXB<sub>2</sub> to functional assay or other downstream metabolite may potentially identify true aspirin nonresponders and individuals who may benefit from modification of their antiplatelet therapy.</p>
<p>When aspirin resistance is identified, we are still faced with an unclear path of effective antiplatelet therapy. Many studies have compared the effect of aspirin versus clopidogrel or combination of both in the prevention of primary or secondary vascular events.<sup>
<xref ref-type="bibr" rid="bibr99-1076029612449197">99</xref>
<xref ref-type="bibr" rid="bibr100-1076029612449197"/>
<xref ref-type="bibr" rid="bibr101-1076029612449197"/>–<xref ref-type="bibr" rid="bibr102-1076029612449197">102</xref>
</sup> A number of antiplatelet options such as clopidogrel, dipyridamole plus aspirin, and cilostazolthat are used if the patient does not respond to aspirin. Newer antiplatelet drugs such as the P2Y<sub>12</sub> inhibitors ticagrelor and prasugrel have been investigated versus clopidogrel for the reduction of vascular events with positive outcomes.<sup>
<xref ref-type="bibr" rid="bibr103-1076029612449197">103</xref>,<xref ref-type="bibr" rid="bibr104-1076029612449197">104</xref>
</sup> Several studies are now in progress that are addressing the role of switching from aspirin to another antiplatelet therapy. The Aspirin Non-responsiveness and Clopidogrel Endpoint Trial (ASCET) is an ongoing study of the superiority of switching to clopidogrel versus continuing aspirin in aspirin-resistant patients with angiographically proven coronary artery disease.<sup>
<xref ref-type="bibr" rid="bibr105-1076029612449197">105</xref>
</sup> The Research Evaluation to Study Individuals Who Show Thromboxane or P2Y(12) Receptor Resistance (RESISTOR) trial will be evaluating whether alternating antiplatelet regimens could prevent myonecrosis after endovascular coronary procedures in patients with aspirin and clopidogrel resistance.<sup>
<xref ref-type="bibr" rid="bibr106-1076029612449197">106</xref>
</sup>
</p>
<p>In conclusion, platelet activation and the activation of the coagulation cascade is modulated by a variety of mechanisms. Due to the complexity of the atherothrombotic process, it cannot necessarily be inhibited by an antagonistic approach of 1 pathway only. Therefore, the broad definition of “treatment failure,” without considering improper/inadequate inhibition of an enzyme or receptor, must be reconsidered.<sup>
<xref ref-type="bibr" rid="bibr10-1076029612449197">10</xref>
</sup> Thus, there is a great need to develop assays that monitor global hemostasis (combined activation of platelet and coagulation pathways). Until such a point-of-care method is available, combinations of biomarkers may best describe the hemostatic balance and better predict the risk of adverse events. A single functional platelet study is insufficient to provide this global measure due to the multiple factors unrelated to aspirin therapy that affect these results. For aspirin, the ratio of an indicator of compliance, such as serum TXB<sub>2</sub>, and a downstream stable metabolite, such as urinary 11-DTB<sub>2</sub> and PGI<sub>2</sub>, may identify at-risk individuals who truly have aspirin resistance.<sup>
<xref ref-type="bibr" rid="bibr107-1076029612449197">107</xref>
</sup> The downstream metabolites may provide a measure of nonplatelet sources of thromboxane that can contribute to overall hemostasis. In addition, elevation of these stable metabolites may be an indication of waxing and waning response to aspirin, perhaps due to ongoing platelet production. Our hypothesis is that a high urinary 11-DTB<sub>2</sub> or PGI<sub>2</sub> and low serum TXB<sub>2</sub> will identify a population that is compliant with aspirin therapy but has persistent reactivity of the COX pathways. Further studies are essential to validate whether the levels of these metabolites will predict the risk of future acute vascular events in patients on aspirin prophylaxis. In addition, these studies are needed to develop newer and more effective alternate antiplatelet therapies for individuals who have been clearly documented with true aspirin resistance.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Eliza W. Hartley for her assistance in editing the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029612449197">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029612449197">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: supported in part by the Office of the Vice President for Research and Minnesota Medical Foundation at the University of Minnesota.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029612449197">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoffhines</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The discovery of aspirin's antithrombotic effects</article-title>. <source>Tex Heart Inst J</source>. <year>2007</year>;<volume>34</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr2-1076029612449197">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furie</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Kasner</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>1</issue>):<fpage>227</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr3-1076029612449197">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Bushnell</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>2</issue>):<fpage>517</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr4-1076029612449197">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brott</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Abbara</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <year>2011</year> <article-title>ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the american college of cardiology foundation/American Heart Association task force on practice guidelines, and the American Stroke Association, american association of neuroscience nurses, american association of neurological surgeons, american college of radiology, american society of neuroradiology, congress of neurological surgeons, society of atherosclerosis imaging and prevention, society for cardiovascular angiography and interventions, society of interventional radiology, society of neurointerventional surgery, society for vascular medicine, and society for vascular surgery</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>8</issue>): <fpage>e464</fpage>–<lpage>e540</lpage>.</citation>
</ref>
<ref id="bibr5-1076029612449197">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laine</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tarnawski</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Gastric mucosal defense and cytoprotection: bench to bedside</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>135</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr6-1076029612449197">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serebruany</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Steinhubl</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>PB</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>95</volume>(<issue>10</issue>):<fpage>1218</fpage>–<lpage>1222</lpage>.</citation>
</ref>
<ref id="bibr7-1076029612449197">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Godwin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warlow</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>The united kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1991</year>;<volume>54</volume>(<issue>12</issue>):<fpage>1044</fpage>–<lpage>1054</lpage>.</citation>
</ref>
<ref id="bibr8-1076029612449197">
<label>8</label>
<citation citation-type="journal">
<collab collab-type="author">Antithrombotic Trialists' Collaboration</collab>. <article-title>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>324</volume>(<issue>7329</issue>):<fpage>71</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr9-1076029612449197">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cattaneo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2004</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1980</fpage>–<lpage>1987</lpage>.</citation>
</ref>
<ref id="bibr10-1076029612449197">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuliczkowski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Witkowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Polonski</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Interindividual variability in the response to oral antiplatelet drugs: a position paper of the working group on antiplatelet drugs resistance appointed by the section of cardiovascular interventions of the polish cardiac society, endorsed by the working group on thrombosis of the european society of cardiology</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>435</lpage>.</citation>
</ref>
<ref id="bibr11-1076029612449197">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: a new independent predictor of vascular events?</article-title> <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>6</issue>):<fpage>966</fpage>–<lpage>968</lpage>.</citation>
</ref>
<ref id="bibr12-1076029612449197">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>14</issue>):<fpage>1650</fpage>–<lpage>1655</lpage>.</citation>
</ref>
<ref id="bibr13-1076029612449197">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grotemeyer</surname>
<given-names>KH</given-names>
</name>
</person-group>. <article-title>Effects of acetylsalicylic acid in stroke patients evidence of nonresponders in a subpopulation of treated patients</article-title>. <source>Thromb Res</source>. <year>1991</year>;<volume>63</volume>(<issue>6</issue>):<fpage>587</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr14-1076029612449197">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grotemeyer</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Scharafinski</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Husstedt</surname>
<given-names>IW</given-names>
</name>
</person-group>. <article-title>Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients</article-title>. <source>Thromb Res</source>. <year>1993</year>;<volume>71</volume>(<issue>5</issue>):<fpage>397</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr15-1076029612449197">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gum</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kottke-Marchant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Poggio</surname>
<given-names>ED</given-names>
</name>
<etal/>
</person-group>. <article-title>Profile and prevalence of aspirin resistance in patients with cardiovascular disease</article-title>. <source>Am J Cardiol</source>. <year>2001</year>;<volume>88</volume>(<issue>3</issue>):<fpage>230</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr16-1076029612449197">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gum</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kottke-Marchant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>White</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>6</issue>):<fpage>961</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr17-1076029612449197">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helgason</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bolin</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Development of aspirin resistance in persons with previous ischemic stroke</article-title>. <source>Stroke</source>. <year>1994</year>;<volume>25</volume>(<issue>12</issue>):<fpage>2331</fpage>–<lpage>2336</lpage>.</citation>
</ref>
<ref id="bibr18-1076029612449197">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howard</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>Aspirin resistance</article-title>. <source>Ann Pharmacother</source>. <year>2002</year>;<volume>36</volume>(<issue>10</issue>):<fpage>1620</fpage>–<lpage>1624</lpage>.</citation>
</ref>
<ref id="bibr19-1076029612449197">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurlen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seljeflot</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Arnesen</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction</article-title>. <source>Scand Cardiovasc J</source>. <year>1998</year>;<volume>32</volume>(<issue>4</issue>):<fpage>233</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr20-1076029612449197">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Salat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stangl</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Variable platelet response to low-dose asa and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty</article-title>. <source>Thromb Haemost</source>. <year>1997</year>;<volume>78</volume>(<issue>3</issue>):<fpage>1003</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr21-1076029612449197">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Besta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Massberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schonig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gawaz</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement</article-title>. <source>Thromb Haemost</source>. <year>2003</year>;<volume>89</volume>(<issue>5</issue>):<fpage>783</fpage>–<lpage>787</lpage>.</citation>
</ref>
<ref id="bibr22-1076029612449197">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patrono</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>FitzGerald</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</article-title>. <source>Chest</source>. <year>2004</year>;<volume>126</volume>(<issue>suppl 3</issue>):<fpage>234S</fpage>–<lpage>264</lpage>S.</citation>
</ref>
<ref id="bibr23-1076029612449197">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollack</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>For some, aspirin may not help hearts</article-title>. <source>The New York Times</source>. <year>2004</year>.</citation>
</ref>
<ref id="bibr24-1076029612449197">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sane</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>McKee</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Malinin</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Serebruany</surname>
<given-names>VL</given-names>
</name>
</person-group>. <article-title>Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin</article-title>. <source>Am J Cardiol</source>. <year>2002</year>;<volume>90</volume>(<issue>8</issue>):<fpage>893</fpage>–<lpage>895</lpage>.</citation>
</ref>
<ref id="bibr25-1076029612449197">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smout</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stansby</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Aspirin resistance</article-title>. <source>Br J Surg</source>. <year>2002</year>;<volume>89</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr26-1076029612449197">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Przytulski</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schanz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hohlfeld</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schror</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Towards a definition of aspirin resistance: a typological approach</article-title>. <source>Platelets</source>. <year>2002</year>;<volume>13</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr27-1076029612449197">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Hoak</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency</article-title>. <source>Lancet</source>. <year>1974</year>;<volume>2</volume>(<issue>7886</issue>):<fpage>924</fpage>–<lpage>926</lpage>.</citation>
</ref>
<ref id="bibr28-1076029612449197">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Balbay</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Korkmaz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Aspirin resistance</article-title>. <source>Anadolu Kardiyol Derg</source>. <year>2004</year>;<volume>4</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr29-1076029612449197">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmermann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wenk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>5</issue>):<fpage>542</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr30-1076029612449197">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hovens</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Snoep</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Eikenboom</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>van der Bom</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Huisman</surname>
<given-names>MV</given-names>
</name>
</person-group>. <article-title>Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>153</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr31-1076029612449197">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patrono</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: definition, mechanisms and clinical read-outs</article-title>. <source>J Thromb Haemost</source>. <year>2003</year>;<volume>1</volume>(<issue>8</issue>):<fpage>1710</fpage>–<lpage>1713</lpage>.</citation>
</ref>
<ref id="bibr32-1076029612449197">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Thom</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>(<issue>17</issue>):<fpage>1705</fpage>–<lpage>1712</lpage>.</citation>
</ref>
<ref id="bibr33-1076029612449197">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berrouschot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schwetlick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>von Twickel</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin resistance in secondary stroke prevention</article-title>. <source>Acta Neurol Scand</source>. <year>2006</year>;<volume>113</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr34-1076029612449197">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Englyst</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Horsfield</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>CD</given-names>
</name>
</person-group>. <article-title>Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2008</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1196</fpage>–<lpage>1203</lpage>.</citation>
</ref>
<ref id="bibr35-1076029612449197">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krasopoulos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brister</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Beattie</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis</article-title>. <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7637</issue>):<fpage>195</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr36-1076029612449197">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georgiadis</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Cordina</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2011</year>.</citation>
</ref>
<ref id="bibr37-1076029612449197">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Aspirin resistance</article-title>. <source>Lancet</source>. <year>2006</year>;<volume>367</volume>(<issue>9510</issue>):<fpage>606</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr38-1076029612449197">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Violi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pignatelli</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The need for a consistent definition of “aspirin resistance”</article-title>. <source>J Thromb Haemost</source>. <year>2006</year>;<volume>4</volume>(<issue>7</issue>):<fpage>1618</fpage>–<lpage>1619</lpage>.</citation>
</ref>
<ref id="bibr39-1076029612449197">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets</article-title>. <source>Am J Hematol</source>. <year>1981</year>;<volume>11</volume>(<issue>4</issue>):<fpage>355</fpage>–<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr40-1076029612449197">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Favaloro</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Clinical utility of the pfa-100</article-title>. <source>Semin Thromb Hemost</source>. <year>2008</year>;<volume>34</volume>(<issue>8</issue>):<fpage>709</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr41-1076029612449197">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Favaloro</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>The utility of the pfa-100 in the identification of von willebrand disease: a concise review</article-title>. <source>Semin Thromb Hemost</source>. <year>2006</year>;<volume>32</volume>(<issue>5</issue>):<fpage>537</fpage>–<lpage>545</lpage>.</citation>
</ref>
<ref id="bibr42-1076029612449197">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eugster</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reinhart</surname>
<given-names>WH</given-names>
</name>
</person-group>. <article-title>The influence of the haematocrit on primary haemostasis in vitro</article-title>. <source>Thromb Haemost</source>. <year>2005</year>;<volume>94</volume>(<issue>6</issue>):<fpage>1213</fpage>–<lpage>1218</lpage>.</citation>
</ref>
<ref id="bibr43-1076029612449197">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>IJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>1999</year>;<volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr44-1076029612449197">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jaschonek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kleine</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Topka</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Aspirin non-responder status in patients with recurrent cerebral ischemic attacks</article-title>. <source>J Neurol</source>. <year>2003</year>;<volume>250</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr45-1076029612449197">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugnicourt</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Roussel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Canaple</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lamy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Godefroy</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Aspirin non-responder status and early neurological deterioration: a prospective study</article-title>. <source>Clin Neurol Neurosurg</source>. <year>2011</year>;<volume>113</volume>(<issue>3</issue>):<fpage>196</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr46-1076029612449197">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PY</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin resistance and adverse clinical events in patients with coronary artery disease</article-title>. <source>Am J Med</source>. <year>2007</year>;<volume>120</volume>(<issue>7</issue>):<fpage>631</fpage>–<lpage>635</lpage>.</citation>
</ref>
<ref id="bibr47-1076029612449197">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poston</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2006</year>;<volume>131</volume>(<issue>1</issue>):<fpage>122</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr48-1076029612449197">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tantry</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>9</issue>):<fpage>1705</fpage>–<lpage>1709</lpage>.</citation>
</ref>
<ref id="bibr49-1076029612449197">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin ‘resistance': role of pre-existent platelet reactivity and correlation between tests</article-title>. <source>J Thromb Haemost</source>. <year>2008</year>;<volume>6</volume>(<issue>12</issue>):<fpage>2035</fpage>–<lpage>2044</lpage>.</citation>
</ref>
<ref id="bibr50-1076029612449197">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grove</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Hvas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Johnsen</surname>
<given-names>HL</given-names>
</name>
<etal/>
</person-group>. <article-title>A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease</article-title>. <source>Thromb Haemost</source>. <year>2010</year>;<volume>103</volume>(<issue>6</issue>):<fpage>1245</fpage>–<lpage>1253</lpage>.</citation>
</ref>
<ref id="bibr51-1076029612449197">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wurtz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>LN</given-names>
</name>
<etal/>
</person-group>. <article-title>Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>(<issue>8</issue>):<fpage>828</fpage>–<lpage>835</lpage>.</citation>
</ref>
<ref id="bibr52-1076029612449197">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>(<issue>25</issue>):<fpage>2586</fpage>–<lpage>2596</lpage>.</citation>
</ref>
<ref id="bibr53-1076029612449197">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catella</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
</person-group>, <article-title>FitzGerald</article-title> <article-title>GA. 11-dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1986</year>;<volume>83</volume>(<issue>16</issue>):<fpage>5861</fpage>–<lpage>5865</lpage>.</citation>
</ref>
<ref id="bibr54-1076029612449197">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patrono</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ciabattoni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pugliese</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pierucci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>FitzGerald</surname>
<given-names>GA</given-names>
</name>
</person-group>. <article-title>Estimated rate of thromboxane secretion into the circulation of normal humans</article-title>. <source>J Clin Invest</source>. <year>1986</year>;<volume>77</volume>(<issue>2</issue>):<fpage>590</fpage>–<lpage>594</lpage>.</citation>
</ref>
<ref id="bibr55-1076029612449197">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McConnell</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>SN</given-names>
</name>
<etal/>
</person-group>. <article-title>Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction</article-title>. <source>Stroke</source>. <year>2004</year>;<volume>35</volume>(<issue>3</issue>):<fpage>727</fpage>–<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr56-1076029612449197">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McConnell</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mansbach</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin and urinary 11-dehydrothromboxane b2 in african american stroke patients</article-title>. <source>Stroke</source>. <year>2002</year>;<volume>33</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr57-1076029612449197">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hishinuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>GSP</given-names>
</name>
<name>
<surname>Takabatake</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of the thromboxane/prostacyclin balance in human urine by gas chromatography/selected ion monitoring: abnormalities in diabetics</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>1996</year>;<volume>54</volume>(<issue>6</issue>):<fpage>445</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr58-1076029612449197">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McConnell</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Cheryk</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Durocher</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke</article-title>. <source>Neurosci Lett</source>. <year>2001</year>;<volume>313</volume>(<issue>1-2</issue>):<fpage>88</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr59-1076029612449197">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizugakia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hishinuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Monitoring of the thromboxane a2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method</article-title>. <source>Prostaglandins Other Lipid Mediat</source>. <year>1999</year>;<volume>58</volume>(<issue>5-6</issue>):<fpage>253</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr60-1076029612449197">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montine</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Sonnen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Milne</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Breitner</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in adapt</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>2</issue>): <fpage>e9340</fpage>.</citation>
</ref>
<ref id="bibr61-1076029612449197">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Heavner</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group>. <article-title>Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2′-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke</article-title>. <source>Toxicol Sci</source>. <year>2001</year>;<volume>59</volume>(<issue>2</issue>):<fpage>316</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr62-1076029612449197">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Liesener</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schanz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hohlfeld</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schror</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Habitual smoking causes an abnormality in platelet thromboxane a2 metabolism and results in an altered susceptibility to aspirin effects</article-title>. <source>Platelets</source>. <year>2000</year>;<volume>11</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr63-1076029612449197">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>DiChiara</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-induced Platelet Effect (ASPECT) Study</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>(<issue>25</issue>):<fpage>3156</fpage>–<lpage>3164</lpage>.</citation>
</ref>
<ref id="bibr64-1076029612449197">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brambilla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parolari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Camera</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery</article-title>. <source>Thromb Haemost</source>. <year>2010</year>;<volume>103</volume>(<issue>3</issue>):<fpage>516</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr65-1076029612449197">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vermillet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boval</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease</article-title>. <source>Thromb Haemost</source>. <year>2011</year>;<volume>105</volume>(<issue>2</issue>):<fpage>336</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr66-1076029612449197">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lordkipanidze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pharand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schampaert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Turgeon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Palisaitis</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Diodati</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>14</issue>):<fpage>1702</fpage>–<lpage>1708</lpage>.</citation>
</ref>
<ref id="bibr67-1076029612449197">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GH</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: a fact or a myth?</article-title> <source>Exp Clin Cardiol</source>. <year>2005</year>;<volume>10</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr68-1076029612449197">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GHR</given-names>
</name>
<name>
<surname>Divani</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Past present and future of anti-platelet therapy</article-title>. <source>J Vascular and Interventional Neurology</source>. <year>2008</year>;<volume>1</volume>:<fpage>57</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr69-1076029612449197">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Michiels</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: does it exist?</article-title> <source>Semin Thromb Hemost</source>. <year>2007</year>;<volume>33</volume>(<issue>2</issue>):<fpage>210</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr70-1076029612449197">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GH</given-names>
</name>
</person-group>. <article-title>Aspirin: expectations and limitations</article-title>. <source>J Assoc Physicians India</source>. <year>2008</year>;<volume>56</volume>:<fpage>317</fpage>–<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr71-1076029612449197">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Luciardi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muntaner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?</article-title> <source>Thromb J</source>. <year>2004</year>;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>.</citation>
</ref>
<ref id="bibr72-1076029612449197">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hurlen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arnesen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Seljeflot</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease</article-title>. <source>Thromb Res</source>. <year>2002</year>;<volume>108</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr73-1076029612449197">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>DI</given-names>
</name>
</person-group>. <article-title>Determination of individual response to aspirin therapy using the accumetrics ultegra rpfa-asa system</article-title>. <source>Point of Care</source>. <year>2004</year>;<volume>3</volume>(<issue>2</issue>):<fpage>77</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr74-1076029612449197">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Caetano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cerletti</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: a revival of platelet aggregation tests?</article-title> <source>J Thromb Haemost</source>. <year>2003</year>;<volume>1</volume>(<issue>9</issue>):<fpage>2048</fpage>–<lpage>2050</lpage>.</citation>
</ref>
<ref id="bibr75-1076029612449197">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuring</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haseroth</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Janson</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Falkenstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Wehling</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100)</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>1999</year>;<volume>37</volume>(<issue>12</issue>):<fpage>584</fpage>–<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr76-1076029612449197">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malinin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spergling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muhlestein</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Steinhubl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Serebruany</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>2004</year>;<volume>15</volume>(<issue>4</issue>):<fpage>295</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr77-1076029612449197">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKee</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sane</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Deliargyris</surname>
<given-names>EN</given-names>
</name>
</person-group>. <article-title>Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance</article-title>. <source>Thromb Haemost</source>. <year>2002</year>;<volume>88</volume>(<issue>5</issue>):<fpage>711</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr78-1076029612449197">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sambola</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heras</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>The PFA-100<sup>®</sup> detects sub-optimal antiplatelet responses in patients on aspirin</article-title>. <source>Platelets</source>. <year>2004</year>;<volume>15</volume>(<issue>7</issue>):<fpage>439</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr79-1076029612449197">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kothari</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Bahl</surname>
<given-names>VK</given-names>
</name>
</person-group>. <article-title>Aspirin resistance: myth or reality?</article-title> <source>Indian Heart J</source>. <year>2003</year>;<volume>55</volume>(<issue>3</issue>):<fpage>217</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr80-1076029612449197">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divani</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Majidi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Noorbaloochi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luft</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>Consequences of stroke in community-dwelling elderly: the health and retirement study, 1998 to 2008</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>7</issue>):<fpage>1821</fpage>–<lpage>1825</lpage>.</citation>
</ref>
<ref id="bibr81-1076029612449197">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Col</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fanale</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Kronholm</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly</article-title>. <source>Arch Intern Med</source>. <year>1990</year>;<volume>150</volume>(<issue>4</issue>):<fpage>841</fpage>–<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr82-1076029612449197">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Bohn</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Mogun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Avorn</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Noncompliance with antihypertensive medications</article-title>. <source>J Gen Intern Med</source>. <year>2002</year>;<volume>17</volume>(<issue>7</issue>):<fpage>504</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr83-1076029612449197">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carney</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Freedland</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>AS</given-names>
</name>
</person-group>. <article-title>Major depression and medication adherence in elderly patients with coronary artery disease</article-title>. <source>Health Psychol</source>. <year>1995</year>;<volume>14</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr84-1076029612449197">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rieckmann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kronish</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes</article-title>. <source>Am Heart J</source>. <year>2006</year>;<volume>152</volume>(<issue>5</issue>):<fpage>922</fpage>–<lpage>927</lpage>.</citation>
</ref>
<ref id="bibr85-1076029612449197">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sappok</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Faulstich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stuckert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kruck</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Marx</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Koennecke</surname>
<given-names>HC</given-names>
</name>
</person-group>. <article-title>Compliance with secondary prevention of ischemic stroke: a prospective evaluation</article-title>. <source>Stroke</source>. <year>2001</year>;<volume>32</volume>(<issue>8</issue>):<fpage>1884</fpage>–<lpage>1889</lpage>.</citation>
</ref>
<ref id="bibr86-1076029612449197">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komiya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Urabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing</article-title>. <source>Stroke</source>. <year>1994</year>;<volume>25</volume>(<issue>12</issue>):<fpage>2337</fpage>–<lpage>2342</lpage>.</citation>
</ref>
<ref id="bibr87-1076029612449197">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuisset</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Frere</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Quilici</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>157</volume>(<issue>5</issue>):<fpage>889</fpage>–<lpage>893</lpage>.</citation>
</ref>
<ref id="bibr88-1076029612449197">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Franco</surname>
<given-names>AC</given-names>
</name>
</person-group>. <article-title>Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients</article-title>. <source>J Transl Med</source>. <year>2008</year>;<volume>6</volume>:<fpage>46</fpage>.</citation>
</ref>
<ref id="bibr89-1076029612449197">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shemesh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zehavi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?</article-title> <source>Am Heart J</source>. <year>2004</year>;<volume>147</volume>(<issue>2</issue>):<fpage>293</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr90-1076029612449197">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watala</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boncler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gresner</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus</article-title>. <source>Pharmacol Rep</source>. <year>2005</year>;<volume>57</volume>(<issue>suppl</issue>):<fpage>42</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr91-1076029612449197">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmermann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Hohlfeld</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Aspirin “resistance”</article-title>. <source>Herz</source>. <year>2008</year>;<volume>33</volume>(<issue>4</issue>):<fpage>270</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr92-1076029612449197">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuern</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gawaz</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management</article-title>. <source>Semin Thromb Hemost</source>. <year>2009</year>;<volume>35</volume>(<issue>3</issue>):<fpage>295</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr93-1076029612449197">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rafferty</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin resistance and compliance with therapy</article-title>. <source>Cardiovasc Ther</source>. <year>2011</year>;<volume>29</volume>(<issue>5</issue>):<fpage>301</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr94-1076029612449197">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beigel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hod</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fefer</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>107</volume>(<issue>3</issue>):<fpage>339</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr95-1076029612449197">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beigel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matetzky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fefer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dvir</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hod</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Aspirin—issues in daily practice: an update</article-title>. <source>Isr Med Assoc J</source>. <year>2007</year>;<volume>9</volume>(<issue>4</issue>):<fpage>221</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr96-1076029612449197">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pulcinelli</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Riondino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Celestini</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Persistent production of platelet thromboxane a2 in patients chronically treated with aspirin</article-title>. <source>J Thromb Haemost</source>. <year>2005</year>;<volume>3</volume>(<issue>12</issue>):<fpage>2784</fpage>–<lpage>2789</lpage>.</citation>
</ref>
<ref id="bibr97-1076029612449197">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>GHR</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions</article-title>. <source>Thromb Res</source>. <year>1986</year>;<volume>44</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr98-1076029612449197">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shantsila</surname>
<given-names>E</given-names>
</name>
</person-group>, <article-title>Lip G. “Aspirin resistance” or treatment non-compliance: which is to blame for cardiovascular complications?</article-title> <source>J Transl Med</source>. <year>2008</year>;<volume>6</volume>:<fpage>47</fpage>.</citation>
</ref>
<ref id="bibr99-1076029612449197">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diener</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Bogousslavsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brass</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2004</year>;<volume>364</volume>(<issue>9431</issue>):<fpage>331</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr100-1076029612449197">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markus</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Droste</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Kaps</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>(<issue>17</issue>):<fpage>2233</fpage>–<lpage>2240</lpage>.</citation>
</ref>
<ref id="bibr101-1076029612449197">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>7</issue>):<fpage>494</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr102-1076029612449197">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>(<issue>10</issue>):<fpage>1202</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr103-1076029612449197">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>CH</given-names>
</name>
<etal/>
</person-group>. <article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>20</issue>):<fpage>2001</fpage>–<lpage>2015</lpage>.</citation>
</ref>
<ref id="bibr104-1076029612449197">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Budaj</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>11</issue>):<fpage>1045</fpage>–<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr105-1076029612449197">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Seljeflot</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Abdelnoor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arnesen</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design</article-title>. <source>Scand Cardiovasc J</source>. <year>2004</year>;<volume>38</volume>(<issue>6</issue>):<fpage>353</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr106-1076029612449197">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W-H</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>DI</given-names>
</name>
</person-group>. <article-title>Aspirin resistance or variable response or both?</article-title> <source>Am J Cardiol</source>. <year>2006</year>;<volume>98</volume>(<issue>10</issue>): <fpage>S11</fpage>–<lpage>S17</lpage>.</citation>
</ref>
<ref id="bibr107-1076029612449197">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geske</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Guyer</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Ens</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Aspirinworks: a new immunologic diagnostic test for monitoring aspirin effect</article-title>. <source>Mol Diagn Ther</source>. <year>2008</year>;<volume>12</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>54</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>